癌症治疗的创新策略之一是利用患者免疫系统的各种成分来增强抗肿瘤免疫反应，疫苗接种是这一策略的一种形式。通过合理设计的纳米颗粒，可以最大程度地提高癌症疫苗的效果，其中包括免疫刺激性佐剂的应用。而纳米颗粒可以控制免疫增强化合物的药代动力学和目标。基于聚-γ-谷氨酸（γ-PGA）的纳米颗粒（NP）源于自然界，易于被树突状细胞（DCs）摄取，从而导致细胞因子的分泌，改善T细胞的刺激能力。γ-PGA NP具有固有的佐剂特性和抗原载体特性，近期的研究对其在调节肿瘤微环境、促进全身抗肿瘤免疫力和抑制肿瘤生长方面发挥的潜力进行了全面的概述。本综述提供了关于γ-PGA NP作为抗癌疫苗抗原载体和／或佐剂的潜力的全面概述。版权所有 2023 Elsevier B.V.发表。

Vaccination is an innovative strategy for cancer treatment by leveraging various components of the patients' immunity to boost an anti-tumor immune response. Rationally designed nanoparticles are well suited to maximize cancer vaccination by the inclusion of immune stimulatory adjuvants. Also, nanoparticles might control the pharmacokinetics and destination of the immune potentiating compounds. Poly-γ-glutamic acid (γ-PGA) based nanoparticles (NPs), which have a natural origin, can be easily taken up by dendritic cells (DCs), which leads to the secretion of cytokines which ameliorates the stimulation capacity of T cells. The intrinsic adjuvant properties and antigen carrier properties of γ-PGA NPs have been the focus of recent investigations as they can modulate the tumor microenvironment, can contribute to systemic anti-tumor immunity and subsequently inhibit tumor growth. This review provides a comprehensive overview on the potential of γ-PGA NPs as antigen carriers and/or adjuvants for anti-cancer vaccination.Copyright © 2023. Published by Elsevier B.V.